title: Recent advances in understanding and treating vasculitis.
abstract: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are near universally fatal conditions if untreated. Although effective therapeutic options are available for these diseases, treatment regimens are associated with both short- and long-term adverse effects. The recent identification of effective B-cell-targeted therapy with an anti-CD20 monoclonal antibody has transformed the treatment landscape of AAV. Questions, nevertheless, remain regarding the appropriate timing, dose, frequency, duration, and long-term effects of treatment. The aim of this article is to provide an overview of the current information, recent advances, ongoing clinical trials, and future treatment possibilities in AAV.
authors.affiliation: Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Koster
authors.affiliation: Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA.
authors.forename: Kenneth J
authors.initials: KJ
authors.lastname: Warrington
keywords: ANCA-associated vasculitides; B-cell; systemic vasculitides; vasculitis